Aprea Therapeutics, Inc. (APRE)
Data as of , from SEC Form 4 filings.
See up to 3 months of APRE. The 7-day demo opens the 1M and 3M ranges and puts APRE on your watchlist.
Start 7-day demoLatest APRE insider trades
About Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
- DOYLESTOWN, PA
- 8
- 2019
- XNAS
APRE Form 4 activity by transaction type, last 90 days
No Form 4 activity for APRE in the last 90 days.
APRE insider transactions (Form 4)
4024 Form 4 filings on record, the earliest from Oct 15, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michael Grissinger - Director | Grant or award | Stock Options (Right to Buy) | 12,555 | $0.00 | - | |
| Michael Grissinger - Director | Grant or award | Common Stock | 3,135 footnote F1 | $0.00 | - | |
| ||||||
| Gabriela Gruia - Director | Grant or award | Common Stock | 3,135 footnote F1 | $0.00 | - | |
| Gabriela Gruia - Director | Grant or award | Stock Options (Right to Buy) | 12,555 | $0.00 | - | |
| ||||||
 Richard Peters - Director | Grant or award | Common Stock | 3,135 footnote F1 | $0.00 | - | |
| Richard Peters - Director | Grant or award | Stock Options (Right to Buy) | 12,555 | $0.00 | - | |
| ||||||
| John B. Henneman III - Director | Grant or award | Common Stock | 3,135 footnote F1 | $0.00 | - | |
| John B. Henneman III - Director | Grant or award | Stock Options (Right to Buy) | 12,555 | $0.00 | - | |
| ||||||
| Jean-Pierre Bizzari - Director | Grant or award | Common Stock | 3,135 footnote F1 | $0.00 | - | |
| Jean-Pierre Bizzari - Director | Grant or award | Stock Options (Right to Buy) | 12,555 | $0.00 | - | |
| ||||||
| Marc Duey - Director | Grant or award | Stock Options (Right to Buy) | 12,555 | $0.00 | - | |
| Marc Duey - Director | Grant or award | Common Stock | 3,135 footnote F1 | $0.00 | - | |
| ||||||
 Rifat Pamukcu - Director | Grant or award | Common Stock | 3,135 footnote F1 | $0.00 | - | |
| Rifat Pamukcu - Director | Grant or award | Stock Options (Right to Buy) | 12,555 | $0.00 | - | |
| ||||||
| Bernd R. Seizinger - Director | Grant or award | Stock Options (Right to Buy) | 12,555 | $0.00 | - | |
| Bernd R. Seizinger - Director | Grant or award | Common Stock | 3,135 footnote F1 | $0.00 | - | |
| ||||||
| John P. Hamill - Officer | Open-market purchase | Pre-Funded Warrant | 30,978 | $0.81 | $25K | |
| John P. Hamill - Officer | Open-market purchase | Common Warrant | 30,978 | - footnote F1 | - | |
| ||||||
| Richard Peters - Director | Open-market purchase | Pre-Funded Warrant | 123,915 | $0.81 | $100K | |
| Richard Peters - Director | Open-market purchase | Common Warrant | 123,915 | - footnote F1 | - | |
| ||||||
 Oren Gilad - Officer | Grant or award | Common Stock | 20,175 footnote F1 | $0.00 | - | |
| Oren Gilad - Officer | Grant or award | Stock Options (Right to Buy) | 80,700 | $0.00 | - | |
| ||||||
| John P. Hamill - Officer | Grant or award | Common Stock | 10,095 footnote F1 | $0.00 | - | |
| John P. Hamill - Officer | Grant or award | Stock Options (Right to Buy) | 40,380 | $0.00 | - | |
| ||||||
| Oren Gilad - Officer | Open-market purchase | Common Stock | 28,100 footnote F2 | $0.89 | $25K | |
| Oren Gilad - Officer | Open-market purchase | Common Warrant | 28,100 | - footnote F3,F4 | - | |
| ||||||
| John P. Hamill - Officer | Open-market purchase | Common Stock | 5,700 footnote F1 | $0.89 | $5K | |
| John P. Hamill - Officer | Open-market purchase | Common Warrant | 5,700 | - footnote F2,F3 | - | |
| ||||||
| John B. Henneman III - Director | Grant or award | Common Stock | 1,045 | $0.00 | - | |
| John B. Henneman III - Director | Grant or award | Stock Options (Right to Buy) | 4,185 | $0.00 | - | |
| Marc Duey - Director | Open-market sale | Common Stock | 6,462 | $4.58 | $30K | |
| Oren Gilad - Officer | Open-market purchase | Common Stock | 500 | $3.92 | $2K | |
| Marc Duey - Director | Open-market purchase | Common Stock | 30,000 | $4.39 | $132K | |
| Oren Gilad - Officer | Open-market purchase | Common Stock | 250 | $2.90 | $725 | |
| Marc Duey - Director | Open-market purchase | Common Stock | 190 | $2.58 | $490 | |
| John P. Hamill - Officer | Open-market purchase | Common Stock | 50 | $2.46 | $123 | |
| Bernd R. Seizinger - Director | Open-market purchase | Common Stock | 10,000 | $2.68 | $27K | |
| Oren Gilad - Officer | Open-market purchase | Common Stock | 150 | $2.54 | $381 | |
| Oren Gilad - Officer | Open-market purchase | Common Stock | 1,000 | $2.59 | $3K | |
| John P. Hamill - Officer | Open-market purchase | Common Stock | 450 | $2.61 | $1K | |
Item 8.01, 9.01
Item 2.02, 8.01, 9.01
Item 3.01
Item 5.07
APRE insider trading FAQ
What is the latest insider trade for APRE?
Aprea Therapeutics, Inc. (APRE) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-06-17. The full record for APRE runs to 24 Form 4 filings, the earliest from 2024-10-15. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying APRE stock?
No insider purchases of APRE were filed in the last 90 days. 17 purchases are on record for this company.
How many insiders are selling APRE stock?
No insider sales of APRE were filed in the last 90 days. 1 sale is on record for this company.
Where can I see APRE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects APRE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Michael Grissinger view on EDGAR
- - Gabriela Gruia view on EDGAR
- - Richard Peters view on EDGAR
- - John B. Henneman III view on EDGAR
- - Jean-Pierre Bizzari view on EDGAR
- - Marc Duey view on EDGAR
- - Rifat Pamukcu view on EDGAR
- - Bernd R. Seizinger view on EDGAR
- - John P. Hamill view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where APRE's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow APRE with a 7-day demo
- APRE on your watchlist
- Every APRE Form 4 filing on record
- Up to 3 months of APRE price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
